Similar Search Results

Eligibility and Inclusiveness of Long-Term Care Institutional Frameworks in Europe : A Cross-Country Comparison

Carrino, Ludovico - 2014

of inclusiveness with respect to vulnerable elderly's health status. Focusing on several European countries, this paper … that substantial heterogeneities exist both at the extensive margin (the health-outcomes that are included in the …

Persistent link: https://www.econbiz.de/10013039883

Pharmaceutical Regulation at the Wholesale Level and Parallel Trade

Birg, Laura - 2014

This paper studies the effect of pharmaceutical regulation at the wholesale level, if markets are integrated by parallel trade, i.e. trade outside the manufacturers authorized distribution channel. In particular, maximum wholesale margins, a restriction of pricing by the intermediary, and...

Persistent link: https://www.econbiz.de/10013061754

Price caps versus reimbursement limits : pharmaceutical regulation under market integration through parallel trade

Birg, Laura - 2019 - Revised Version March 2019

In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...

Persistent link: https://www.econbiz.de/10011986314

How to Integrate Administrative Law and Tort Law : The Regulation of Stem Cell Products

Munzer, Stephen R. - 2013

This article offers a proposal for the regulation of stem cell products by the Food and Drug Administration (“FDA”) that corresponds to a specialized product liability scheme. It shows how product liability and administrative law can be successfully integrated to create a comprehensive legal...

Persistent link: https://www.econbiz.de/10014162099

The Impact of the Entry of Biosimilars : Evidence from Europe

Scott Morton, Fiona M.; Stern, Ariel Dora; Stern, Scott - 2019

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics...

Persistent link: https://www.econbiz.de/10014126235

The Problems Created by the Rising Food Prices and Prices for Other Vital Goods During the Current Pandemic

Levashenko, Antonina; Girich, Maris - 2020

During the COVID-19 pandemic, prices for a number of consumer goods and services, as well as for some pharmaceutical and medicines products, have increased significantly. To counter the attempts of unscrupulous sellers to increase their profits by price gouging, the governments of several OECD...

Persistent link: https://www.econbiz.de/10014096077

International Price Regulations in the Pharmaceutical Sector : A Common Model to Sharing the Benefits

Levaggi, Rosella; Capri, Stefano - 2005

In this article we analyse the market for drugs in health care markets where third payers (an insurance company or a …

Persistent link: https://www.econbiz.de/10014028693

Advancing patient safety governance in the COVID-19 response

de Bienassis, Katherine - 2023

challenge. This once-in-a-century global health crisis exposed the vulnerability of healthcare delivery systems and the …In the backdrop of the COVID-19 pandemic, ensuring the safety of health care services remains a serious, ongoing … strengthening health system resilience. …

Persistent link: https://www.econbiz.de/10014278981

The Impact of Pharmaceutical Policy Measures : A Structural-Break Approach

Barros, Pedro P.; Nunes, Luis C. - 2009

Pharmaceutical spending in many other countries has had a steep increase in the last decade. The Portuguese Government has adopted several measures to reduce pharmaceutical expenditure growth, ranging from increased co-payments to price decreases determined administratively. Promotion of generic...

Persistent link: https://www.econbiz.de/10014209702

Comparative Effectiveness Research (CER) Policies and the Potential Threat to Pharmaceutical Innovation

Vernon, John A. - 2013

As health care reform evolves and takes shape, comparative effectiveness research appears to be one of the central … topics on the national health care agenda. Over the past couple of years, comparative effectiveness has been explicitly … of efficient resource allocation within U.S. health care markets. However, the future operationalization and …

Persistent link: https://www.econbiz.de/10013094926